It remains to be seen if the relative difference in inhibition of γc cytokine receptors vs other cytokine receptors (eg, IFN and IL‐6) with tofacitinib, compared with JAK inhibitors that spare JAK3, translates into a meaningful difference in infection risk. The gene discussed is JAK3; the disease is infection.